Article
Healthcare Utilization and Clinical Outcomes of Lanadelumab: Insights from Spain's First Cohort of Difficult-to-Treat Hereditary Angioedema Patients
2024-10-08
Abstract excerpt
Hereditary angioedema (HAE) is a rare genetic disorder clinically characterized by recurrent episodes of severe swelling, affecting the skin, gastrointestinal tract, and airways. Lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, is approved for long-term prophylaxis (LTP) in HAE patients, demonstrating effectiveness in reducing disease burden. This study evaluated the real-world impact of lanadel...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 14c6e919-95f1-58ff-8a17-3e5030d0e380
- DOI
- 10.20944/preprints202410.0490.v1
